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Myeloid Deletion of Nemo Causes 
Osteopetrosis in Mice Owing to 
Upregulation of Transcriptional 
Repressors
Gaurav Swarnkar1, Kyuhwan Shim1, Amjad M. Nasir1, Kuljeet Seehra1, Hung-Po (Tim) Chen1, 
Gabriel Mbalaviele2 & Yousef Abu-Amer1
The transcription factor NF-κB is central to numerous physiologic processes including bone 
development, and its activation is controlled by IKKγ (also called NEMO), the regulatory subunit 
of IKK complex. NEMO is X-linked, and mutations in this gene result in Incontinentia Pigmenti in 
human hemizygous females. In mice, global deficiency causes embryonic lethality. In addition, 
certain point mutations in the NEMO (IKBKG) human gene manifest skeletal defects implicating 
NEMO in the regulation of bone homeostasis. To specifically investigate such role, we conditionally 
deleted Nemo from osteoclast and myeloid progenitors. Morphometric, histologic, and molecular 
analyses demonstrate that myeloid NEMO deletion causes osteopetrosis in mice. Mechanistically, 
NEMO deficiency hampered activation of IKK complex in osteoclast precursors, causing arrest of 
osteoclastogenesis and apoptosis. Interestingly, inhibiting apoptosis by genetic ablation of TNFr1 
significantly increased cell survival, but failed to rescue osteoclastogenesis or reverse osteopetrosis. 
Based on this observation, we analyzed the expression of different regulators of osteoclastogenesis 
and discovered that NEMO deletion leads to increased RBPJ expression, resulting in a decrease of 
Blimp1 expression. Consequently, expression of IRF8 and Bcl6 which are targets of Blimp1 and potent 
osteoclastogenic transcriptional repressors, is increased. Thus, NEMO governs survival and osteoclast 
differentiation programs through serial regulation of multiple transcription factors.
The transcription factor NF-κ B, which encompasses a family of transcription factors, was initially identified in 
B cells and subsequently was shown to be ubiquitously expressed in all cell types1. Although early studies high-
lighted the role of NF-κ B as a modulator of innate and adaptive immunity, subsequent research established a 
central role for this factor in ample physiologic cellular functions2. More importantly, NF-κ B was further impli-
cated in pathological conditions and diseases, including inflammation, cancer, metabolic disorders, and skeletal 
disparities, prompting the design of NF-κ B based relevant therapeutic modalities3–5.
NF-κ B signaling entails transmission of receptor-activating signals leading to assembly and activation of 
a signalosome complex that includes adaptor proteins and kinases. The most notable members of this com-
plex are TRAF protein ligases, the scaffold protein IKKƴ/NEMO and the catalytic subunits IKK1 and IKK2. 
Signal-specific recruitment, assembly and activation of this complex lead to further recruitment of substrates such 
as the NF-κ B inhibitory protein Iκ B. Once at the proximity of IKK, Iκ B undergoes phosphorylation, ubiquitina-
tion and proteosome-mediated degradation. Subsequently, the active subunits of NF-κ B including p65/RelA, p50 
are released, translocate to the nucleus, bind to consensus DNA motifs, and initiate transcription6–10.
The individual role of most members in the NF-κ B signaling in various cells has been studied in details using 
gene knockout studies6,11,12. The surprising discovery in the late 1990s that NF-κ B is key regulator of bone home-
ostasis13 ignited a new era of discoveries aimed at understanding the role of NF-κ B members and signals in bone 
health and disease. In this regard, tissue-specific deletion of most members of the NF-κ B pathway, notably IKK1, 
IKK2, Iκ B, RelA, and combined deletion of p50/p52 displayed skeletal anomalies3,14,15. However, the direct role 
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of NEMO in bone homeostasis was not described. Nevertheless, numerous studies suggest that NEMO is indeed 
an essential component of NF-κ B mediated skeletal homeostasis. In this regard, we and others have shown that 
NEMO binding domain peptide, which acts as a decoy to attenuate IKK activation, inhibits osteoclasts and oste-
olysis16–21. Furthermore, several patient case reports described association between specific NEMO mutations and 
abnormal skeletal manifestations22–25. These observations suggest that NEMO maybe directly required for skeletal 
development and homeostasis.
Despite this massive effort, decoding the precise repertoire of NF-κ B action under physiologic and patho-
logic conditions remains an overwhelming challenge. In this regard, a relentless effort continues to decipher the 
molecular role of IKKƴ/NEMO as a signal integrator and a scaffold protein pairing upstream cellular responses 
with kinase-targeted selection of appropriate substrates in a cell-specific manner26. Supporting this contention is 
a recent report indicating that NEMO determined stimulus-specific transduction by directing the IKK complex 
hub toward Iκ Bα 27. Thus, it appears that the extent of NEMO functions as a master regulator of NF-κ B signaling 
remains underappreciated.
In order to examine the role of NEMO in skeletal development, we conditionally deleted the gene in the mye-
loid compartment using various monocyte/macrophage and osteoclast lineage-specific Cre deleters. Mice devoid 
of NEMO in these cells developed severe osteopetrosis owing to defective osteoclastogenesis. At the molecular 
level, this defect arises from dysregulation of NF-κ B-dependent transcriptional machinery in the myeloid lineage.
Results
Mice lacking NEMO in myeloid lineage are smaller and display developmental disparities. To 
assess the direct role of NEMO in skeletal development, we specifically deleted NEMO in myeloid progenitor cells 
and osteoclast-committed precursor cells by crossing Nemo-floxed mice with Lysozyme-M-Cre (NM-cKO−LysM, 
referred to as NM-cKO throughout the manuscript) or Cathepsin-K (CTSK)-Cre (NM-cKO−CTSK), respectively, 
at early (progenitor) or late (osteoclast) lineage differentiation stages. Initial examination shows that NM-cKO 
mice are smaller in size and display growth and developmental retardation (Fig. 1A left panel). Further examina-
tion shows that long bones of NM-cKO are hypo-cellular and these mice displayed splenomegaly consistent with 
extra-medullary hematopoiesis (Fig. 1A right panel). Genotyping PCR (not shown) and Western blot analyses 
confirmed efficient deletion of NEMO evident by minimal expression of NEMO in NM-cKO mice (Fig. 1B, top 
panel). This was further supported by failure to activate IKK2 (Fig. 1B, middle panel) and subsequent phos-
phorylation of Iκ B (p-Iκ B) or phosphorylation of exogenous GST-Iκ B substrate (Fig. 1C) following treatments 
with receptor activator of nuclear factor kappa-B ligand (RANKL or RL), confirming that NEMO is required for 
RANKL-induced activation of NF-κ B pathway.
Myeloid-specific deletion of NEMO causes an osteopetrotic phenotype in mice. Next, we exam-
ined the effect of NEMO deletion on skeletal development. Micro-CT analysis of the long bones indicates that 
both NM-cKO−LysM (Fig. 2A–F) and NM-cKO−CTSK (Fig. 2G–L) mice show denser bones in both the trabec-
ular (Fig. 2A,G) and cortical regions (Fig. 2B,H; arrows). Consistently, all bone parameters including BV/TV 
(Fig. 2C,I), trabecular number (Fig. 2D,J), trabecular thickness (Fig. 2E,K) and trabecular spacing (Fig. 2F,L) indi-
cate that both genotypes of NM-cKO mice display osteopetrotic phenotype. These results confirm that NEMO is 
critical for normal skeletal development at early and late stages.
Osteopetrosis in NEMO-null mice is due to hampered osteoclast differentiation and decreased 
cell survival. To better understand the mechanism underlying the osteopetrotic phenotype of NM-cKO mice, 
we examined tartrate-resistant acid phosphatase (TRAP)-stained histological sections of the trabecular regions of 
long bones and found significantly less osteoclasts in NM-cKO compared with wild type bone sections (Fig. 3A). 
This finding suggested that impaired osteoclastogenesis in vivo is likely the primary culprit of osteopetrosis in 
NM-cKO mice. To further decipher the details of this osteoclast abnormality, we examined differentiation and 
survival of NEMO-deficient progenitors and pre-osteoclasts in vitro. The results indicate that NM-cKO-derived 
marrow cells exhibit impaired osteoclast differentiation potential evident by significantly less osteoclast for-
mation in vitro (Fig. 3B) and by reduced expression of molecular markers of osteoclast differentiation, includ-
ing TRAP, Cathepsin-K (CTSK), Matrix metallopeptidase 9 (MMP9), and Nuclear Factor of Activated T-Cells 
Calcineurin-Dependent 1 (NFATc1) (Fig. 3C).
The hypo-cellularity of the long bones suggested a potential cell survival impediment. To scrutinize this pos-
sibility, we analyzed apoptosis using fluorescence-activated cell sorting (FACS)-based apoptosis and Western 
blot assays. Indeed, our results confirmed that NM-cKO myeloid progenitor cells are prone to apoptosis, but not 
necrosis, as shown by increased staining for the apoptotic marker annexin V within the CD11b+ /Gr1+ NM-cKO 
cell populations (Fig. 4A, lower panels) when compared to WT cells (Fig. 4A, top panels). Similarly Western blot 
data indicates an increase in cleaved Caspase-3 and PARP1 expression (Fig. 4B). Consistent with FACS data, there 
was no change in RIP3 expression between both phenotypes (Fig. 4C), indicating that necrosis is not the mecha-
nism underlying cell death in Nemo-deficient cells.
Neutralization of TNFα or deletion of TNFr1 protects NEMO- null cells from apoptosis but 
fails to rescues defective osteoclastogenesis. To test if cell apoptosis is the underlying cause of 
reduced osteoclastogenesis and osteopetrosis in NM-cKO, we employed in vitro and in vivo approaches. First, 
NM-cKO-derived progenitor cells were incubated in the continuous presence of TNFα neutralizing antibody 
to avert apoptosis, and osteoclastogenesis was measured. Second, NM-cKO mice were bred with germline 
TNFr1-null mice to generate NEMO/TNFr1 double knockout mice (NM/TNFr1-dKO) to attenuate any possi-
ble apoptotic signal at the outset of NEMO deletion. FACS analysis shows that neutralization of TNFα restored 
survival and protected NM-cKO cells from apoptosis (Fig. 5A; compare with Fig. 4). This rescue, however, failed 
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to recapitulate osteoclastogenesis (Fig. 5B). In contrast, osteoclastogenesis and cell survival were restored by 
retroviral expression of WT-NEMO (pMX-NEMO) in the NM-cKO cells (5B) buttressing the requirement of 
NEMO for cell survival and osteoclast differentiation. Consistent with these results, bone marrow cells from 
NM/TNFr1-dKO animal failed to differentiate into osteoclasts as evident by TRAP staining (Fig. 5C) and by 
mRNA expression of osteoclast marker genes (Fig. 5D). In summary, in both in vitro and in vivo cases, osteoclas-
togenesis was significantly reduced with persistent skeletal osteopetrotic features in the NM/TNFr1-dKO mice 
(not shown). Collectively, these data suggest that intact NEMO is essential for NF-κ B signaling, myeloid lineage 
survival and osteoclast differentiation.
NEMO regulates osteoclastogenesis via RBPJ-Blimp1 axis. Despite rescue of the apoptotic phe-
notype of NM-cKO, NEMO deficient BMMs failed to differentiate into osteoclasts. To better clarify the possi-
ble mechanism regulating NEMO function in these cells, we studied the expression of other known regulators 
of osteoclastogenesis. Recombination signal binding protein for immunoglobulin kappa J region (RBPJ) has 
been described as a negative regulator of osteoclastogenesis. Specifically, it plays a repressor role during oste-
oclastogenesis especially under inflammatory conditions. In this respect, we showed recently that inactivation 
of NF-κ B signaling is accompanied with accumulation of RBPJ, which along with other co-repressors inhibit 
osteoclasts28. Furthermore, RBPJ has been shown to regulate osteoclastogenesis via different mechanisms, such 
as TAK1-RBPJ axis28, Blimp1-IRF8 axis29 or via regulating TGFβ –PLCƴ2 axis30. To this end, we measured the 
expression of RBPJ, Blimp1, IRF8 and Bcl6 in NEMO/TNFr1-dKO cells. Our Western blot results indicate that 
Figure 1. NEMO-myeloid deficient mice are smaller and display developmental defects. NEMO was deleted 
using LysM and CTSK mediated cre. (A) Photomicrograph of Lysozyme-cre-NEMO floxed (NM-cKO−LysM) 
mice (left panel) and bone and spleen (right panel) compared to WT mice. (B,C) Western blot analysis of WT 
and NM-cKO cells lysates showing deletion of NEMO (48 kDa, panel B) and attenuation of NF-κ B signaling 
as evident by lack of IKK2 (p-IKK2 = 87 kDa, IKK2 = 85 kDa) and Iκ B (p-Iκ B = 40 kDa, Iκ B = 39 kDa) 
phosphorylation in panels B and C, respectively, in NEMO null cells upon RANKL stimulation (50 ng/mL) for 
the time points indicated. β -Actin (42 kDa) was used as loading control.
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under NEMO deficiency, RBPJ expression was significantly increased under basal (2.5 fold) and RANKL (3.9 
fold) stimulated conditions (Fig. 6A). qPCR analysis confirmed significant decrease in the expression of RBPJ 
target, B lymphocyte-induced maturation protein-1 (Blimp1), and subsequent increased interferon regulatory 
factor 8 (IRF8) expression (Fig. 6B), which can inhibit osteoclastogenesis by suppressing expression of the osteo-
clast master regulator NFATc1 (see Fig. 5D). Under similar culture conditions we found that whereas expression 
levels of the NFATc1 repressor B cell lymphoma-6 (BCL6) were reduced in RANKL-treated wild type cells to 
permit osteoclastogenesis, no such reduction was evident in NM/TNFr1-dKO cells when compared to untreated 
cells (Fig. 6C). Collectively, these data (summarized in Fig. 6D) suggest that during osteoclastogenesis, absence 
of NEMO attenuates NF-κ B signaling which leads to elevated levels of the transcriptional repressor RBPJ. RBPJ 
in turn inhibits Blimp1 leading to increased expression of IRF8 and Bcl6, both of which inhibit expression of the 
master osteoclast gene NFATc1 (see also Figs 3C and 5D) and attenuate osteoclastogenesis. In addition, NEMO 
deletion leads to cell apoptosis through TNFα -mediated caspase signals.
Discussion
The transcription factor NF-κ B is a master regulator of ubiquitous cellular functions and cell fate, and is essential 
for maintaining physiologic homeostasis31. NEMO, which lacks catalytic activity, serves as a scaffold platform to 
regulate IKK complex assembly32. Furthermore, recent studies suggest that NEMO is a signaling hub that facil-
itates and couples various signals with downstream substrates27. Therefore, understanding the intricate details 
of NEMO-mediated signals will open new and unexplored research opportunities. Although the role of several 
NF-κ B molecules in skeletal homeostasis has been elucidated12,15, the direct role of NEMO, the master regulator 
of NF-κ B pathways, in bone has not been directly addressed.
In this study, we document two major observations. First, we show that tissue-specific deletion of NEMO in 
the myeloid lineage compromises cell survival. Second, this deletion leads to the development of skeletal dispar-
ities, primarily osteopetrosis. The pro-survival role of NF-κ B signaling has been further elucidated and our data 
ascertain that NEMO plays an essential role in this phenomenon. More importantly, we provide clear evidence 
that restoring cell survival by attenuating death signals, typically transmitted through TNFr1 signaling, does 
not restore osteoclastogenesis. Thus, NEMO plays multiple non-redundant roles in cell survival and osteoclas-
togenesis. We further posit that the osteopetrotic phenotype arises directly from defective osteoclastogenesis and 
from scarcity of osteoclast progenitor cells in the marrow cavity of long bones, as evident by hypo-cellularity in 
the tibiae and femora of NM-cKO mice. Intriguingly, we observed splenomegaly in NM-cKO mice, indicating 
extra-medullary hematopoiesis and obstructive marrow hematopoiesis. Thus, NEMO expression and baseline 
NF-κ B activity are required for normal bone marrow hematopoiesis.
Osteoclastogenesis is governed by intricate transcriptional machinery at the apex of which is NF-κ B-mediated 
basal transcription. Further, ample evidence suggest that NF-κ B regulates transcription of numerous genes that 
determine the fate of osteoclast differentiation and survival12. In this regard, we have shown recently that deletion 
Figure 2. Myeloid-specific deletion of NEMO in mice leads to osteopetrotic bone phenotype. (A,B) Micro-CT 
images of distal femur diaphysis and quantification of (C) bone volume (BV/TV), (D) Trabecular number (Tb.N), 
(E) Trabecular thickness (Tb.Th) and (F) Trabecular spacing (Tb.Sp) from female, 5 weeks old control and NM-
cKOLysM mice. Lower panel; (G,H) Micro-CT images and quantification of (I) bone volume (BV/TV),  
(J) Trabecular number (Tb.N), (K) Trabecular thickness (Tb.Th) and (L) Trabecular spacing (Tb.Sp) from female, 
5 weeks control and NM-cKO−CTSK mice (n = 6–8; * P < 0.05). Arrows point to cortical and trabecular regions. 
Horizontal lines across the diaphysis in B and H indicate approximate locations from which images A and G, 
respectively, were constructed.
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of TGFβ -activated Kinase-1 (TAK1) and subsequent impairment of NF-κ B activation is accompanied with high 
expression of the transcription factor RBPJ, which acts as a transcriptional repressor of osteoclastogenesis28. 
Earlier studies have shown that the NF-κ B member p65/RelA, an immediate downstream target of NEMO/IKK2 
classical pathway, and RBPJ share an overlapping binding site at different gene promoters, including NFATc133,34. 
In other studies, our group and Zhao et al. showed that RBPJ inhibits osteoclastogenesis by inhibiting NFATc1 
expression via suppressing Blimp-1, which prevents the downregulation of the transcriptional repressor IRF829,35. 
Furthermore, Miyauchi et al. showed that osteoclast transcriptional repressor B cell lymphoma-6 (Bcl6) is a 
direct target of Blimp136. Our study provides compelling evidence that inactivation of NF-κ B through deletion 
of NEMO facilitates accumulation of RBPJ and associated co-repressors. Our data further show that under these 
conditions, expression levels of Blimp1, a target of RBPJ and inducer of osteoclastogenesis, are reduced, hence 
permitting high expression of IRF8 and Bcl6, both of which repress expression of the osteoclast master regulator 
NFATc1 and impede osteoclastogenesis (Fig. 6D). It is important to note that NEMO appears to be essential for 
RANKL-induced repression of Bcl6 (Fig. 6C), which subsequently permits osteoclast gene transcription. In this 
regard, it has been proposed that some macrophage-specific enhancers contain NF-κ B binding sites and recruit 
such factors upon stimulation and that these enhancers are negatively inhibited by sequence-specific transcrip-
tional repressors, namely Bcl637. We posit that NEMO deletion, which plummets NF-κ B transcriptional activity, 
permits RANKL-specific enhancer repression through elevated levels of Bcl6. This is a novel finding that warrants 
further investigation. Taken together, our study identifies NEMO as a RANKL-dependent regulator of transcrip-
tional machinery that controls osteoclastogenesis and bone homeostasis.
Methods
Animals. Nemo floxed mice on a C57BL/6 background, generously provided by Dr. Manolis Pasparakis 
(Cologne, Germany) were crossed with LysM-Cre (Jacksons Laboratories) and CTSK-cre mice38 to produce het-
erozygous mice. The NEMO heterozygous mice were further intercrossed to generate homozygous null mice 
(NM-cKO−LysM or NM-cKO−CTSK). To delete the TNFr1 gene, germline TNFr1-null mice (Jacksons Laboratories) 
were crossed with NM-cKO−LysM to generate heterozygous mice, which were further intercrossed to generate 
homozygous NEMO and TNFr1 double knock out mice (NM/TNFr1-dKO). Mice were housed at the Washington 
University School of Medicine barrier facility. All experimental protocols were carried out in accordance with the 
Figure 3. Osteopetrosis in NEMO-null mice is due to hindered osteoclast differentiation. (A) WT and NM-
cKO (NM-cKO−LysM ) mice (3-4 weeks old; n = 6 per group) were sacrificed, and long bones were processed for 
histology, stained with TRAP (left panel) to visualize osteoclasts and innumerate osteoclast counts per bone 
area (right panel) using Osteomeasure. (B) BMMs were isolated from NM-cKO and WT mice. Cells were plated 
with M-CSF (20 ng/mL) and RANKL (50 ng/mL) for 4 days and then fixed and TRAP-stained (left panel) and 
counted (right panel). (C) PCR quantification of osteoclast genes ikbkg (NEMO), tracp (TRAP), Cathepsin-K 
(CTSK), NFATc1, and MMP9. (* P < 0.05, * * P < 0.01, * * * P < 0.001).
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ethical guidelines approved by the Washington University School of Medicine Institutional Animal Care and Use 
Committee.
Cell culture and osteoclastogenesis. Bone marrow cells were cultured in α -MEM supplemented with 
100 units/mL penicillin/streptomycin and 10% FBS (v/) with 10 ng/mL M-CSF for 16 h to separate adherent cells 
from non-adherent cells. Non-adherent cells were harvested and used as enriched bone marrow–derived mono-
cyte/macrophage precursors (i.e., BMMs). BMMs were further cultured with M-CSF (20 ng/mL) and RANKL 
(50 ng/mL) for 4 days followed by fixation and TRAP staining using TRAP-Leukocyte kit (Sigma, St Louis, MO, 
USA). TRAP-positive cells containing more than three nuclei were considered multinucleated bona fide osteo-
clasts. In certain conditions, NM-cKO cells were either cultured with TNFα neutralizing antibody (0.2 μ g/mL) 
or transfected with retroviral pMX-WT-NEMO generated by transfecting pMX-WT-NEMO in Plat-E cells as 
described previously28.
Western blot analysis. To study phosphorylation and expression of proteins in osteoclasts, BMMs were 
induced with RANKL for different time points as described in the figures and the total cell lysates were pre-
pared in cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA). Protein concentration was determined 
and equal amount of protein was applied onto SDS-PAGE. After the transfer, membranes were blocked in 5% 
skimmed milk for 1 h at room temperature, followed by probing with specific primary antibody primary anti-
bodies in 5% BSA in PBS-Tween (1% v/v) overnight and then washed three times with PBS-Tween (PBST) and 
probed with secondary antibodies from LI-COR (Odyssey Imager; donkey anti-rabbit/IRDye 800 CW/anti-goat/
IRDye 800 CW anti-mouse IRDye 680 CW) for 1 h at room temperature. Membranes were then washed three 
times with PBST and scanned by using LI-COR Odyssey Imager (LI-COR Biosciences, Lincoln, NE, USA). The 
RBPJ, NEMO, IKK2, pIκ B, Iκ B and cleaved PARP1 antibodies were purchased form Santa Cruz, Dallas, TX, USA; 
Cleaved Caspase 3 antibody was purchased from Cell Signaling Technology, Danvers, MA, USA; β -actin was 
purchased from Sigma, St Louis, MO, USA.
Figure 4. Apoptosis in myeloid-specific NEMO-null mice. (A) BMMs were isolated from NM-cKO 
(NM-cKO−LysM) and WT mice, cultured overnight in α -MEM supplemented with 10% FBS and 10 ng/mL 
M-CSF and stained for CD11ba and Gr1 followed by Annexin V/7AAD staining. FACS analysis was done to 
determine apoptosis in these cells. The Annexin V positive cells (Q2 - late; Q3- early) in FACS (left panels) 
and quantitation (right panel) are shown. (* * P < 0.01) (B) Western blot indicating increased cleaved PARP1 
(89 kDa) and cleaved Caspase 3 (17 kDa) levels in NM-cKO cell under basal and serum starved condition when 
compared to WT cells. (C) Western blot indicating no change in RIP3 (60 kDa) expression in NM-cKO cells 
when compared with WT cells.
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In vitro kinase assay. WT and NM-cKO BMMS were treated with RANKL for 0, 20 and 40 minutes followed 
by lysis in RIPA buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40, 1 mM EDTA 50 μ g/ml leupeptin, 10 μ g/ml 
aprotinin, 50 μ g/ml phenylmethylsulfonyl fluoride (PMSF), 0.2 mM sodium orthovanadate, 100 mM sodium 
fluorine) for immunoprecipitation. IKK2 complex was immunoprecipitated with NEMO FL-419 (Santa 
Cruz, Dallas, TX, USA) antibody, washed twice with IP buffer, once with kinase assay buffer (Cell Signaling 
Technologies Danvers, MA, USA), and incubated for 30 minutes at 30 °C in 30 μ l kinase assay buffer with 1 μ g 
GST-Iκ Bα , 2.5 mM MgCl2, and 16 μ M ATP. Reaction was terminated with 10 μ l 4 X reducing sample buffer. 
Samples were analyzed by Western blot.
Micro-CT acanning and analysis. Intact femur and tibia from WT mice and NM-cKO animals were iso-
lated, fixed overnight in 10% formalin followed by washing with Phosphate Buffer Saline (PBS) 3 times and trans-
ferred to 70% ethanol (v/v). Bones were then scanned using Scanco Medical micro-CT systems (Scanco, Wayne, 
PA, USA) at the core facility at the musculoskeletal center at Washington University (St. Louis, MO). Briefly, 
Images were scanned at a resolution of 20 μ m, slice increment 20 μ m, voltage 55 kV, current 145 μ A and exposure 
time of 200 ms. After scanning the whole bone, contour was drawn from the growth plate toward trabecular and 
cortical regions of tibia of approximately 200 slices were analyzed for WT and NM-cKO bones, and 3D images 
were constructed.
Histology. Femur and tibia were collected from mice and fixed in 10% buffered formalin for 16–24 h. Bones 
were then decalcified for 2 weeks in decalcification buffer (14% (w/v) EDTA, NH4OH, pH 7.2), dehydrated in 
Figure 5. Assessment of apoptosis and osteoclastogenesis after neutralization of TNFα or deletion of 
TNFr1 in NEMO-null cells. (A) FACS analysis of BMMs isolated from NEMO/TNFr1 double KO (NM/
TNFr1-dKO) and WT mice and stained for CD11ba and Gr1 followed by Annexin V/7AAD staining. Annexin 
V positive cells in FACS (left panel) and quantitation (right panel) are shown. (B) BMMs were isolated from WT 
and NM-cKO mice. NM-cKO cells were cultured with either TNFα neutralizing antibody or infected with WT-
NEMO retrovirus (pMX-NEMO) for 4 days in the presence of M-CSF (20 ng/mL) and RANKL (50 ng/mL) and 
then fixed and TRAP-stained. (C) BMMs were isolated from NEMO/TNFR1 double KO (NM/TNFr1-dKO) 
and WT mice and cultured in the presence of M-CSF (20 ng/mL) and RANKL (50 ng/mL) for 4 days and then 
fixed and TRAP-stained. (D) PCR quantification of OC genes NEMO, TRAP, CTSK, NFATc1, β 3-integrin, and 
MMP9 from WT and (NM/TNFr1-dKO) BMMs. (* * P < 0.01, * * * P < 0.001).
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graded ethanol (30–70%), cleared through xylene, and embedded in paraffin. Paraffin sections were stained for 
TRAP to visualize osteoclasts.
qPCR analysis. Cells were cultured in presence of M-CSF (20 ng/mL) and RANKL (50 ng/mL) for 3 or 4 days 
as labeled in the figures. mRNA was isolated using PureLink RNA mini kit (Ambion, Grand Island, NY, USA) and 
cDNA were prepared using high capacity cDNA reverse transcription kit (Applied Biosystems). qPCR was car-
ried out on BioRad CFX96 real time system using iTaq universal SYBR green super-mix (BioRad, Hercules, CA, 
USA). mRNA expression were normalized using actin as a housekeeping gene. The following primers were used 
for qPCR analysis. TRAP-F: CGACCATTGTTAGCCACATACG, TRAP-R: CACATAGCCCACACCGTTCTC, 
CTSK-F: ATGTGGGTGTTCAAGTTTCTGC, CTSK-R: CCACAAGATTCTGGGGACTC, MMP9-F: ACTGGG 
CTTAGATCATTCCAGCGT, MMP9-R: ACACCCACATTTGACGTCCAGAGA, NFATc1-F: CCGGGACGCCC 
ATGCAATCTGTTAGT, NFATc1-R: GCGGGTGCCCTGAGAAAGCTACTCTC, NEMO-F: CTAGGAGCTCCGG 
TTCTGTC, NEMO-R: TGCTTGTTCATCCAACAGGA, IRF8-F: GAGCGAAGTTCCTGAGATGG, IRF8-R: TG 
GGCTCCTCTTGGTCATAC, Blimp1-F: GACGGGGGTACTTCTGTTCA, Blipm1-R: GGCATTCTTGGGAA 
CTGTGT, Bcl6-F: AGACGCACAGTGACAAACCATACAA, Bcl6-R: GCTCCACAAATGTTACAGCGATAGG.
FACS analysis. Total bone marrows cells were cultured in α -MEM supplemented with 10% FBS and 10 ng/mL 
M-CSF for 16 hours. Afterwards, cells were washed twice with cold PBS, re-suspended in FACS buffer (PBS sup-
plemented with 0.5% BSA and 2 mM EDTA), incubated with Fc blocker (BD Biosciences, San Jose, CA, USA) 
for 15 minutes before staining with APC Alex 780 conjugated anti-CD11b antibody (eBiosciences, San Diego, 
CA, USA) and Brilliant Violet 421 conjugated Gr-1 antibody (Biolegend, San Diego, CA, USA) for 30 minutes. 
Antibody-labelled cells were then washed with FACS buffer, resuspended in Annexin V binding buffer and 
stained with PE conjugated AnnexinV (BD Biosciences, San Jose, CA, UA) for 15 minutes. After adding 7-AAD, 
flow cytometry data acquisition was performed on FACScan at Washington University High Speed Cell Sorting 
Core Facility and analyzed by FlowJo Version 10.1 (TreeStar, Ashland, OR, USA).
Figure 6. NEMO regulates osteoclastogenesis via inhibiting RBPJ. (A) WT and NM/TNFr1-dKO BMMs 
were treated with RANKL for 0 and 3 days, lysed, and subjected to immunoblotting with RBPJ (56 kDa) 
antibody (1:1000). (B,C) Q-PCR quantification of relative mRNA expression (normalized with actin) of Blimp1, 
IRF8, and Bcl6 in WT and NM/TNFr1-dKO cells under the indicated conditions (+ /− RANKL). (* P < 0.05,  
* * P < 0.01). (D) Proposed model of NEMO function during osteoclastogenesis. Left and right panels illustrate 
regulation of osteoclastogenesis under NEMO sufficient or null conditions, respectively.
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Statistical analysis. All experiments were repeated at least three times. Statistical analyses were performed 
by using Student t-test. Multiple treatments were analyzed by using one-way ANOVA followed by post hoc 
Newman-Keuls test of significance. Values are expressed as mean ± SD of at least three independent experiments. 
P values are indicated where applicable.
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